The FDA issued a tentative approval for Lantheus’ PNT2003, an abbreviated new drug application aimed at replicating Novartis’ Lutathera (lutetium Lu 177 dotatate) for somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors. The tentative clearance arrives amid an active 2024 lawsuit from Novartis alleging multiple patent infringements tied to Lutathera’s formulation and processes. Judge Maryellen Noreika has described the litigation as unusually complex, with Novartis asserting infringement across six patents. Under Hatch–Waxman rules, the litigation raises the prospect of extended stays and protracted discovery that could delay any final commercial entry despite the FDA’s tentative finding of bioequivalence. Radiopharmaceutical experts noted that IP disputes in this class typically hinge on formulation and manufacturing patents rather than novel molecular claims, making the outcome a bellwether for future radioligand generic attempts. Lantheus and rivals such as Curium, pursuing a 505(b)(2) route, now face overlapping legal and regulatory timelines. Stakeholders in radiopharma, hospital pharmacies and investors will watch courtroom developments and any settlement talks closely: a final approval or clearance could materially affect supply, pricing and access for Lutathera-class therapies well before core patents expire in 2038.